Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience
BACKGROUND: The effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are intensely needed. Pazopanib is a selective multitargeted tyrosine kinase inhibitor that has proven to be effective in the treatment of metastatic...
Saved in:
Published in | Translational oncology Vol. 13; no. 2; pp. 295 - 299 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.02.2020
Neoplasia Press Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | BACKGROUND: The effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are intensely needed. Pazopanib is a selective multitargeted tyrosine kinase inhibitor that has proven to be effective in the treatment of metastatic soft tissue sarcomas. The objective of this study was to evaluate the off-label use of pazopanib in patients with metastatic bone sarcomas who failed standard chemotherapy. METHODS: All patients with metastatic bone sarcomas treated with pazopanib between October 1st, 2011 and October 1st, 2017 at the Department of Oncology, Aarhus University Hospital were evaluated. Demographics, treatment, and survival outcomes were collected and analyzed. RESULTS: Nineteen patients were identified. The median age was 38 years (range 18–62). Most of the patients (50%) were diagnosed with osteosarcoma. All patients had documented disease progression at the time of initiating pazopanib treatment. The median overall survival was 11 months. Median progression free survival was 5.4 months. Out of 19 patients, 13 (68%) had either partial response or stable disease. In five patients, the dose of pazopanib was reduced because of toxicity. CONCLUSION: Off-label use of pazopanib is effective in the treatment of metastatic bone sarcomas of different histologies. Pazopanib was well tolerated in the treatment of patients with refractory bone sarcomas. Studies examining the effect of pazopanib alone or in combination with chemotherapy or other targeted therapies are needed. |
---|---|
AbstractList | The effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are intensely needed. Pazopanib is a selective multitargeted tyrosine kinase inhibitor that has proven to be effective in the treatment of metastatic soft tissue sarcomas. The objective of this study was to evaluate the off-label use of pazopanib in patients with metastatic bone sarcomas who failed standard chemotherapy.
All patients with metastatic bone sarcomas treated with pazopanib between October 1st, 2011 and October 1st, 2017 at the Department of Oncology, Aarhus University Hospital were evaluated. Demographics, treatment, and survival outcomes were collected and analyzed.
Nineteen patients were identified. The median age was 38 years (range 18-62). Most of the patients (50%) were diagnosed with osteosarcoma. All patients had documented disease progression at the time of initiating pazopanib treatment. The median overall survival was 11 months. Median progression free survival was 5.4 months. Out of 19 patients, 13 (68%) had either partial response or stable disease. In five patients, the dose of pazopanib was reduced because of toxicity.
Off-label use of pazopanib is effective in the treatment of metastatic bone sarcomas of different histologies. Pazopanib was well tolerated in the treatment of patients with refractory bone sarcomas. Studies examining the effect of pazopanib alone or in combination with chemotherapy or other targeted therapies are needed. BACKGROUND: The effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are intensely needed. Pazopanib is a selective multitargeted tyrosine kinase inhibitor that has proven to be effective in the treatment of metastatic soft tissue sarcomas. The objective of this study was to evaluate the off-label use of pazopanib in patients with metastatic bone sarcomas who failed standard chemotherapy. METHODS: All patients with metastatic bone sarcomas treated with pazopanib between October 1st, 2011 and October 1st, 2017 at the Department of Oncology, Aarhus University Hospital were evaluated. Demographics, treatment, and survival outcomes were collected and analyzed. RESULTS: Nineteen patients were identified. The median age was 38 years (range 18–62). Most of the patients (50%) were diagnosed with osteosarcoma. All patients had documented disease progression at the time of initiating pazopanib treatment. The median overall survival was 11 months. Median progression free survival was 5.4 months. Out of 19 patients, 13 (68%) had either partial response or stable disease. In five patients, the dose of pazopanib was reduced because of toxicity. CONCLUSION: Off-label use of pazopanib is effective in the treatment of metastatic bone sarcomas of different histologies. Pazopanib was well tolerated in the treatment of patients with refractory bone sarcomas. Studies examining the effect of pazopanib alone or in combination with chemotherapy or other targeted therapies are needed. BACKGROUNDThe effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are intensely needed. Pazopanib is a selective multitargeted tyrosine kinase inhibitor that has proven to be effective in the treatment of metastatic soft tissue sarcomas. The objective of this study was to evaluate the off-label use of pazopanib in patients with metastatic bone sarcomas who failed standard chemotherapy. METHODSAll patients with metastatic bone sarcomas treated with pazopanib between October 1st, 2011 and October 1st, 2017 at the Department of Oncology, Aarhus University Hospital were evaluated. Demographics, treatment, and survival outcomes were collected and analyzed. RESULTSNineteen patients were identified. The median age was 38 years (range 18-62). Most of the patients (50%) were diagnosed with osteosarcoma. All patients had documented disease progression at the time of initiating pazopanib treatment. The median overall survival was 11 months. Median progression free survival was 5.4 months. Out of 19 patients, 13 (68%) had either partial response or stable disease. In five patients, the dose of pazopanib was reduced because of toxicity. CONCLUSIONOff-label use of pazopanib is effective in the treatment of metastatic bone sarcomas of different histologies. Pazopanib was well tolerated in the treatment of patients with refractory bone sarcomas. Studies examining the effect of pazopanib alone or in combination with chemotherapy or other targeted therapies are needed. BACKGROUND: The effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are intensely needed. Pazopanib is a selective multitargeted tyrosine kinase inhibitor that has proven to be effective in the treatment of metastatic soft tissue sarcomas. The objective of this study was to evaluate the off-label use of pazopanib in patients with metastatic bone sarcomas who failed standard chemotherapy. METHODS: All patients with metastatic bone sarcomas treated with pazopanib between October 1st, 2011 and October 1st, 2017 at the Department of Oncology, Aarhus University Hospital were evaluated. Demographics, treatment, and survival outcomes were collected and analyzed. RESULTS: Nineteen patients were identified. The median age was 38 years (range 18–62). Most of the patients (50%) were diagnosed with osteosarcoma. All patients had documented disease progression at the time of initiating pazopanib treatment. The median overall survival was 11 months. Median progression free survival was 5.4 months. Out of 19 patients, 13 (68%) had either partial response or stable disease. In five patients, the dose of pazopanib was reduced because of toxicity. CONCLUSION: Off-label use of pazopanib is effective in the treatment of metastatic bone sarcomas of different histologies. Pazopanib was well tolerated in the treatment of patients with refractory bone sarcomas. Studies examining the effect of pazopanib alone or in combination with chemotherapy or other targeted therapies are needed. |
Author | Aggerholm-Pedersen, Ninna Rossen, Phillip Rose, Hanne Safwat, Akmal |
AuthorAffiliation | Department of Oncology, Aarhus University Hospital, Aarhus, Denmark |
AuthorAffiliation_xml | – name: Department of Oncology, Aarhus University Hospital, Aarhus, Denmark |
Author_xml | – sequence: 1 givenname: Ninna surname: Aggerholm-Pedersen fullname: Aggerholm-Pedersen, Ninna email: ninnpe@rm.dk – sequence: 2 givenname: Phillip surname: Rossen fullname: Rossen, Phillip – sequence: 3 givenname: Hanne surname: Rose fullname: Rose, Hanne – sequence: 4 givenname: Akmal surname: Safwat fullname: Safwat, Akmal |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31875575$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kU1v1DAQhi3Uin7AP0AoRy4b_BE7MQcErApUqtRK7N2aOOPWq8Re7GwF_fV1u6W0l55szcfzzsx7RPZCDEjIO0ZrRpn6uK7nBCVWc8p0zXhNKXtFDpkWaiG5EHtP_gfkKOc1pYppzl-TA8G6VspWHpIvF3ATNxB8X_lQzVdYrRLCPGGYq-iqb0Wz-gXJxgnyp2o5-uAtjNXJnw0mj8HiG7LvYMz49uE9JqvvJ6vlz8XZ-Y_T5dezhZVcz4vBciiDIsWmo9pZ6VSjqaSd05Ir3jSKchBMOkF73rUgre37oRGUUQu9EsfkdIcdIqzNJvkJ0l8TwZv7QEyXBtLs7YjGDdhw0Mh51zdy0LrwO9E6a1UPopeF9XnH2mz7CQdbdk0wPoM-zwR_ZS7jtVFaMM5YAXx4AKT4e4t5NpPPFscRAsZtNuXitNW80bqUNrtSm2LOCd2jDKPmzkezNjsfzZ2PhnFTfCxt75-O-Nj0z7j_O2C5-bXHZLK992PwCe1cruJfVrgFOI6x6Q |
CitedBy_id | crossref_primary_10_1002_cam4_4849 crossref_primary_10_3390_cancers12082130 crossref_primary_10_3390_medicina57020141 crossref_primary_10_3390_jpm13050730 crossref_primary_10_1016_j_jbo_2023_100511 crossref_primary_10_1007_s10456_020_09716_y crossref_primary_10_3390_ijms25073834 crossref_primary_10_17816_vto624147 crossref_primary_10_3390_ijms231810721 crossref_primary_10_1002_pbc_29084 crossref_primary_10_1038_s41598_021_87553_9 crossref_primary_10_1080_08880018_2023_2182854 crossref_primary_10_3389_fonc_2023_1013359 crossref_primary_10_1021_acsomega_2c00518 crossref_primary_10_1038_s41571_021_00519_8 crossref_primary_10_1111_1759_7714_15208 crossref_primary_10_3390_ijms21207595 crossref_primary_10_1007_s12254_021_00728_y crossref_primary_10_1089_ten_teb_2023_0106 crossref_primary_10_18632_oncoscience_587 crossref_primary_10_3390_pharmaceutics15020664 crossref_primary_10_1002_ctd2_202 crossref_primary_10_21682_2311_1267_2021_8_1_57_63 |
Cites_doi | 10.1093/annonc/mdy500 10.1158/1078-0432.CCR-09-0816 10.1016/S1470-2045(14)71136-2 10.1080/0284186X.2018.1503714 10.1002/cncr.23437 10.1093/jnci/dju329 10.1002/cncr.24562 10.1016/j.critrevonc.2010.02.012 10.1016/S0140-6736(12)60651-5 10.1200/JCO.2010.30.9674 10.3109/0284186X.2014.948062 10.1007/s12032-018-1180-x 10.1016/S1470-2045(18)30742-3 10.1200/JCO.2003.08.132 10.3109/0284186X.2014.971938 10.1002/cncr.29426 10.2147/CLEP.S41835 |
ContentType | Journal Article |
Copyright | 2019 The Authors Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved. 2019 The Authors 2019 |
Copyright_xml | – notice: 2019 The Authors – notice: Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved. – notice: 2019 The Authors 2019 |
DBID | 6I. AAFTH NPM AAYXX CITATION 7X8 5PM DOA |
DOI | 10.1016/j.tranon.2019.12.001 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1936-5233 |
EndPage | 299 |
ExternalDocumentID | oai_doaj_org_article_fde42a9e228b45d99262837fcc6ba3b5 10_1016_j_tranon_2019_12_001 31875575 S1936523319304073 |
Genre | Journal Article |
GroupedDBID | --- .1- .FO 0SF 1P~ 29Q 2WC 4.4 457 53G 5VS 6I. AACTN AAEDT AAEDW AAFTH AAIKJ AAKDD AALRI AAXUO ABMAC ACGFS ADBBV ADEZE AENEX AEVXI AEXQZ AFCTW AFRHN AFTJW AGHFR AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS BAWUL BCNDV DIK E3Z EBS EJD F5P FDB GROUPED_DOAJ GX1 HYE IPNFZ IXB KQ8 M~E NCXOZ OC~ OK1 OO- RIG ROL RPM SSZ TR2 Z5R 0R~ ADVLN AFJKZ AKRWK NPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c529t-dc2a201e0e4809fc5f6490508f9526244602a315f30b287a5ccbbd43010cab63 |
IEDL.DBID | RPM |
ISSN | 1936-5233 |
IngestDate | Tue Oct 22 15:11:03 EDT 2024 Tue Sep 17 21:28:02 EDT 2024 Fri Oct 25 22:17:36 EDT 2024 Thu Sep 26 19:22:23 EDT 2024 Sat Sep 28 08:29:57 EDT 2024 Wed May 17 02:16:52 EDT 2023 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
License | This is an open access article under the CC BY-NC-ND license. Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c529t-dc2a201e0e4809fc5f6490508f9526244602a315f30b287a5ccbbd43010cab63 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931211/ |
PMID | 31875575 |
PQID | 2330792499 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_fde42a9e228b45d99262837fcc6ba3b5 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6931211 proquest_miscellaneous_2330792499 crossref_primary_10_1016_j_tranon_2019_12_001 pubmed_primary_31875575 elsevier_sciencedirect_doi_10_1016_j_tranon_2019_12_001 |
PublicationCentury | 2000 |
PublicationDate | 2020-02-01 |
PublicationDateYYYYMMDD | 2020-02-01 |
PublicationDate_xml | – month: 02 year: 2020 text: 2020-02-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Translational oncology |
PublicationTitleAlternate | Transl Oncol |
PublicationYear | 2020 |
Publisher | Elsevier Inc Neoplasia Press Elsevier |
Publisher_xml | – name: Elsevier Inc – name: Neoplasia Press – name: Elsevier |
References | Coens, van der Graaf, Blay, Chawla, Judson, Sanfilippo, Manson, Hodge, Marreaud, Prins (bib5) 2015; 121 Grignani, Palmerini, Ferraresi, D'Ambrosio, Bertulli, Asaftei, Tamburini, Pignochino, Sangiolo, Marchesi (bib13) 2015; 16 Seto, Song, Trieu, Yu, Sidhu, Liu, Sam, Pan (bib19) 2019; 7 Urbonas, Schadendorf, Zimmer, Danson, Marshall, Corrie, Wheater, Plummer, Mauch, Scudder (bib21) 2019; 30 Schutz, Choueiri, Sternberg (bib3) 2011; 77 Abdeen, Chou, Healey, Khanna, Osborne, Hewitt, Kim, Wang, Moody, Gorlick (bib6) 2009; 115 Goyal, Shah, Khan, Danish, Haffty (bib22) 2012; 2012 Fox, Aplenc, Bagatell, Chuk, Dombi, Goodspeed, Goodwin, Kromplewski, Jayaprakash, Marotti (bib18) 2010; 28 Raciborska, Bilska (bib12) 2018; 35 Yukata, Matsui, Goto, Kubo, Yasui (bib10) 2005; 25 Safwat, Boysen, Lucke, Rossen (bib15) 2014; 53 Grignani, Palmerini, Dileo, Asaftei, D'Ambrosio, Pignochino, Mercuri, Picci, Fagioli, Casali (bib11) 2012; 23 Maretty-Nielsen, Aggerholm-Pedersen, Keller, Safwat, Baerentzen, Pedersen (bib17) 2013; 5 Wong, Houghton, Kirsch, Finkelstein, Monjazeb, Xu-Welliver, Dicker, Ahmed, Vikram, Teicher (bib23) 2014; 106 Kubo, Piperdi, Rosenblum, Antonescu, Chen, Kim, Huvos, Sowers, Meyers, Healey (bib8) 2008; 112 Kager, Zoubek, Potschger, Kastner, Flege, Kempf-Bielack, Branscheid, Kotz, Salzer-Kuntschik, Winkelmann (bib1) 2003; 21 van der Graaf, Blay, Chawla, Kim, Bui-Nguyen, Casali, Schoffski, Aglietta, Staddon, Beppu (bib4) 2012; 379 Duffaud, Mir, Boudou-Rouquette, Piperno-Neumann, Penel, Bompas, Delcambre, Kalbacher, Italiano, Collard (bib20) 2019; 20 Longhi, Paioli, Palmerini, Cesari, Abate, Setola, Spinnato, Donati, Hompland, Boye (bib16) 2019; 58 (bib2) 2014; 25 Alcindor (bib14) 2015; 54 Manara, Nicoletti, Zambelli, Ventura, Guerzoni, Landuzzi, Lollini, Maira, Garcia-Echeverria, Mercuri, Picci (bib9) 2010; 16 McGary, Weber, Mills, Doucet, Lewis, Lev, Fidler, Bar-Eli (bib7) 2002; 8 McGary (10.1016/j.tranon.2019.12.001_bib7) 2002; 8 Manara (10.1016/j.tranon.2019.12.001_bib9) 2010; 16 Kubo (10.1016/j.tranon.2019.12.001_bib8) 2008; 112 Alcindor (10.1016/j.tranon.2019.12.001_bib14) 2015; 54 Duffaud (10.1016/j.tranon.2019.12.001_bib20) 2019; 20 Urbonas (10.1016/j.tranon.2019.12.001_bib21) 2019; 30 Schutz (10.1016/j.tranon.2019.12.001_bib3) 2011; 77 Raciborska (10.1016/j.tranon.2019.12.001_bib12) 2018; 35 Grignani (10.1016/j.tranon.2019.12.001_bib13) 2015; 16 Safwat (10.1016/j.tranon.2019.12.001_bib15) 2014; 53 Fox (10.1016/j.tranon.2019.12.001_bib18) 2010; 28 Wong (10.1016/j.tranon.2019.12.001_bib23) 2014; 106 Seto (10.1016/j.tranon.2019.12.001_bib19) 2019; 7 Grignani (10.1016/j.tranon.2019.12.001_bib11) 2012; 23 Yukata (10.1016/j.tranon.2019.12.001_bib10) 2005; 25 Goyal (10.1016/j.tranon.2019.12.001_bib22) 2012; 2012 Coens (10.1016/j.tranon.2019.12.001_bib5) 2015; 121 Abdeen (10.1016/j.tranon.2019.12.001_bib6) 2009; 115 Kager (10.1016/j.tranon.2019.12.001_bib1) 2003; 21 van der Graaf (10.1016/j.tranon.2019.12.001_bib4) 2012; 379 Longhi (10.1016/j.tranon.2019.12.001_bib16) 2019; 58 (10.1016/j.tranon.2019.12.001_bib2) 2014; 25 Maretty-Nielsen (10.1016/j.tranon.2019.12.001_bib17) 2013; 5 |
References_xml | – volume: 5 start-page: 45 year: 2013 end-page: 56 ident: bib17 article-title: Population-based Aarhus Sarcoma Registry: validity, completeness of registration, and incidence of bone and soft tissue sarcomas in western Denmark publication-title: Clin Epidemiol contributor: fullname: Pedersen – volume: 21 start-page: 2011 year: 2003 end-page: 2018 ident: bib1 article-title: Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols publication-title: J Clin Oncol contributor: fullname: Winkelmann – volume: 25 start-page: 955 year: 2005 end-page: 957 ident: bib10 article-title: Differential expression of VEGF isoforms and VEGF receptors in cartilaginous tumors publication-title: Anticancer Res contributor: fullname: Yasui – volume: 23 start-page: 508 year: 2012 end-page: 516 ident: bib11 article-title: A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study publication-title: Lancet Oncol contributor: fullname: Casali – volume: 7 year: 2019 ident: bib19 article-title: Real-world experiences with pazopanib in patients with advanced soft tissue and bone sarcoma in Northern California publication-title: Med Sci (Basel) contributor: fullname: Pan – volume: 25 year: 2014 ident: bib2 article-title: Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol – volume: 115 start-page: 5243 year: 2009 end-page: 5250 ident: bib6 article-title: Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma publication-title: Cancer contributor: fullname: Gorlick – volume: 112 start-page: 2119 year: 2008 end-page: 2129 ident: bib8 article-title: Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma publication-title: Cancer contributor: fullname: Healey – volume: 58 start-page: 124 year: 2019 end-page: 128 ident: bib16 article-title: Pazopanib in relapsed osteosarcoma patients: report on 15 cases publication-title: Acta Oncol contributor: fullname: Boye – volume: 77 start-page: 163 year: 2011 end-page: 171 ident: bib3 article-title: Pazopanib: clinical development of a potent anti-angiogenic drug publication-title: Crit Rev Oncol Hematol contributor: fullname: Sternberg – volume: 20 start-page: 120 year: 2019 end-page: 133 ident: bib20 article-title: Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study publication-title: Lancet Oncol contributor: fullname: Collard – volume: 16 start-page: 530 year: 2010 end-page: 540 ident: bib9 article-title: NVP-BEZ235 as a new therapeutic option for sarcomas publication-title: Clin Cancer Res contributor: fullname: Picci – volume: 106 year: 2014 ident: bib23 article-title: Combining targeted agents with modern radiotherapy in soft tissue sarcomas publication-title: J Natl Cancer Inst contributor: fullname: Teicher – volume: 35 start-page: 126 year: 2018 ident: bib12 article-title: Sorafenib in patients with progressed and refractory bone tumors publication-title: Med Oncol (Northwood, London, England) contributor: fullname: Bilska – volume: 2012 start-page: 896202 year: 2012 ident: bib22 article-title: Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with pazopanib publication-title: ISRN Oncol contributor: fullname: Haffty – volume: 379 start-page: 1879 year: 2012 end-page: 1886 ident: bib4 article-title: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial publication-title: Lancet (London, England) contributor: fullname: Beppu – volume: 28 start-page: 5174 year: 2010 end-page: 5181 ident: bib18 article-title: A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors publication-title: J Clin Oncol contributor: fullname: Marotti – volume: 53 start-page: 1451 year: 2014 end-page: 1454 ident: bib15 article-title: Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients publication-title: Acta Oncol (Stockholm, Sweden) contributor: fullname: Rossen – volume: 8 start-page: 3584 year: 2002 end-page: 3591 ident: bib7 article-title: Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571 publication-title: Clin Cancer Res contributor: fullname: Bar-Eli – volume: 121 start-page: 2933 year: 2015 end-page: 2941 ident: bib5 article-title: Health-related quality-of-life results from PALETTE: a randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072) publication-title: Cancer contributor: fullname: Prins – volume: 30 start-page: 317 year: 2019 end-page: 324 ident: bib21 article-title: Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial publication-title: Ann Oncol contributor: fullname: Scudder – volume: 16 start-page: 98 year: 2015 end-page: 107 ident: bib13 article-title: Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial publication-title: Lancet Oncol contributor: fullname: Marchesi – volume: 54 start-page: 1063 year: 2015 end-page: 1064 ident: bib14 article-title: Response of refractory Ewing sarcoma to pazopanib publication-title: Acta Oncol (Stockholm, Sweden) contributor: fullname: Alcindor – volume: 30 start-page: 317 issue: 2 year: 2019 ident: 10.1016/j.tranon.2019.12.001_bib21 article-title: Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial publication-title: Ann Oncol doi: 10.1093/annonc/mdy500 contributor: fullname: Urbonas – volume: 7 issue: 3 year: 2019 ident: 10.1016/j.tranon.2019.12.001_bib19 article-title: Real-world experiences with pazopanib in patients with advanced soft tissue and bone sarcoma in Northern California publication-title: Med Sci (Basel) contributor: fullname: Seto – volume: 2012 start-page: 896202 year: 2012 ident: 10.1016/j.tranon.2019.12.001_bib22 article-title: Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with pazopanib publication-title: ISRN Oncol contributor: fullname: Goyal – volume: 8 start-page: 3584 issue: 11 year: 2002 ident: 10.1016/j.tranon.2019.12.001_bib7 article-title: Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571 publication-title: Clin Cancer Res contributor: fullname: McGary – volume: 16 start-page: 530 issue: 2 year: 2010 ident: 10.1016/j.tranon.2019.12.001_bib9 article-title: NVP-BEZ235 as a new therapeutic option for sarcomas publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-0816 contributor: fullname: Manara – volume: 23 start-page: 508 issue: 2 year: 2012 ident: 10.1016/j.tranon.2019.12.001_bib11 article-title: A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study publication-title: Lancet Oncol contributor: fullname: Grignani – volume: 16 start-page: 98 issue: 1 year: 2015 ident: 10.1016/j.tranon.2019.12.001_bib13 article-title: Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)71136-2 contributor: fullname: Grignani – volume: 58 start-page: 124 issue: 1 year: 2019 ident: 10.1016/j.tranon.2019.12.001_bib16 article-title: Pazopanib in relapsed osteosarcoma patients: report on 15 cases publication-title: Acta Oncol doi: 10.1080/0284186X.2018.1503714 contributor: fullname: Longhi – volume: 112 start-page: 2119 issue: 10 year: 2008 ident: 10.1016/j.tranon.2019.12.001_bib8 article-title: Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma publication-title: Cancer doi: 10.1002/cncr.23437 contributor: fullname: Kubo – volume: 25 start-page: 955 issue: 2A year: 2005 ident: 10.1016/j.tranon.2019.12.001_bib10 article-title: Differential expression of VEGF isoforms and VEGF receptors in cartilaginous tumors publication-title: Anticancer Res contributor: fullname: Yukata – volume: 106 issue: 11 year: 2014 ident: 10.1016/j.tranon.2019.12.001_bib23 article-title: Combining targeted agents with modern radiotherapy in soft tissue sarcomas publication-title: J Natl Cancer Inst doi: 10.1093/jnci/dju329 contributor: fullname: Wong – volume: 115 start-page: 5243 issue: 22 year: 2009 ident: 10.1016/j.tranon.2019.12.001_bib6 article-title: Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma publication-title: Cancer doi: 10.1002/cncr.24562 contributor: fullname: Abdeen – volume: 77 start-page: 163 issue: 3 year: 2011 ident: 10.1016/j.tranon.2019.12.001_bib3 article-title: Pazopanib: clinical development of a potent anti-angiogenic drug publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2010.02.012 contributor: fullname: Schutz – volume: 25 issue: Suppl 3 year: 2014 ident: 10.1016/j.tranon.2019.12.001_bib2 article-title: Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol – volume: 379 start-page: 1879 issue: 9829 year: 2012 ident: 10.1016/j.tranon.2019.12.001_bib4 article-title: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial publication-title: Lancet (London, England) doi: 10.1016/S0140-6736(12)60651-5 contributor: fullname: van der Graaf – volume: 28 start-page: 5174 issue: 35 year: 2010 ident: 10.1016/j.tranon.2019.12.001_bib18 article-title: A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors publication-title: J Clin Oncol doi: 10.1200/JCO.2010.30.9674 contributor: fullname: Fox – volume: 53 start-page: 1451 issue: 10 year: 2014 ident: 10.1016/j.tranon.2019.12.001_bib15 article-title: Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients publication-title: Acta Oncol (Stockholm, Sweden) doi: 10.3109/0284186X.2014.948062 contributor: fullname: Safwat – volume: 35 start-page: 126 issue: 10 year: 2018 ident: 10.1016/j.tranon.2019.12.001_bib12 article-title: Sorafenib in patients with progressed and refractory bone tumors publication-title: Med Oncol (Northwood, London, England) doi: 10.1007/s12032-018-1180-x contributor: fullname: Raciborska – volume: 20 start-page: 120 issue: 1 year: 2019 ident: 10.1016/j.tranon.2019.12.001_bib20 article-title: Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30742-3 contributor: fullname: Duffaud – volume: 21 start-page: 2011 issue: 10 year: 2003 ident: 10.1016/j.tranon.2019.12.001_bib1 article-title: Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols publication-title: J Clin Oncol doi: 10.1200/JCO.2003.08.132 contributor: fullname: Kager – volume: 54 start-page: 1063 issue: 7 year: 2015 ident: 10.1016/j.tranon.2019.12.001_bib14 article-title: Response of refractory Ewing sarcoma to pazopanib publication-title: Acta Oncol (Stockholm, Sweden) doi: 10.3109/0284186X.2014.971938 contributor: fullname: Alcindor – volume: 121 start-page: 2933 issue: 17 year: 2015 ident: 10.1016/j.tranon.2019.12.001_bib5 publication-title: Cancer doi: 10.1002/cncr.29426 contributor: fullname: Coens – volume: 5 start-page: 45 year: 2013 ident: 10.1016/j.tranon.2019.12.001_bib17 article-title: Population-based Aarhus Sarcoma Registry: validity, completeness of registration, and incidence of bone and soft tissue sarcomas in western Denmark publication-title: Clin Epidemiol doi: 10.2147/CLEP.S41835 contributor: fullname: Maretty-Nielsen |
SSID | ssj0061922 |
Score | 2.38002 |
Snippet | BACKGROUND: The effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are... The effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are intensely needed.... BACKGROUNDThe effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are... BACKGROUND: The effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are... |
SourceID | doaj pubmedcentral proquest crossref pubmed elsevier |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 295 |
SubjectTerms | Original article |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA7iQbyIb9cXEbwW0zTJNp58oCzCiuAK3kKSJrgiXdH14q93pmnV1YMXr21pOjNJZr7myxdCDjVSnyrvs4opm4nIbGYlD5kLklWBl2XucYPz8FoN7sTVvbz_dtQXcsKSPHBy3FGsguBWB85LJ2SlUd8OQFX0XjlbuKRemssOTKU5GFEBT-vJCqFW0W2aa5hdU8gCE9Q-zXXzK7A9EKZLSo12_0xu-l17_qRQfstJl8tkqS0m6WkyYoXMhXqVLAzb5fI1cnJj3wEU12NHxzWFUo-OOl45nUR6NqkDvYWejhyhY9pKhD7RL_njdTK6vBidD7L2yITMS66nWeW5BbsCC6JkOnoZldAMirCoJTgOsB_jtshlLJgDrGSl985VAkY589apYoPMg2vCFqE5d0r50oeiDKJyqsTCycmYR-EkzAM9knUuM89JGMN0jLFHk1xs0MUm50ic65Ez9Ovnsyhr3VyAYJs22OavYPdIv4uKaSuElPnhVeM_mj_ogmhgAOGqiK3D5O3VQO9gfUShukc2U1A_PxImvL6EghbanQn3jBWzd-rxQyPSrXSB6nnb_2H2DlnkCPMbsvgumZ--vIU9qIWmbr_p9h_8sgYh priority: 102 providerName: Directory of Open Access Journals – databaseName: ScienceDirect Open Access Journals (Elsevier) dbid: IXB link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3BTtwwELUQB8Slaim0SwG5EtdoHcf2xj3BoiJUiaoSi7Q3y3bsNlWVILpc-vWdSWxo2gNSr0mUODOTmXnx8zMhpxqpT433RcOULURktrCSh8IFyZrA67r0uMD5-rO6uhWf1nK9RS7yWhikVabcP-b0IVunI_Nkzfld285voPVQAKMghgCSQ6RCHkZtT1zEt17mbIz4gI8zywpBV5WXzw0crw3Ugx5VUEs9_BRMW8Pk8jSo-E-q1L9d6N9kyj-q0-VL8iK1lfR8HPkrshW6PbJznSbOX5OzL_YXwOOudbTtKDR9dJUZ5rSPdNl3gd5AzCNb6ANNYqE_6JMQ8j5ZXX5cXVwVafOEwkuuN0XjuYX3CiyImunoZVRCM2jHopZcQVFXjNuqlLFiDlCTld471wj43pm3TlUHZBtME94SWnKnlK99qOogGqdqbKGcjGUUTkJGmJEim8zcjRIZJnPHvpvRxAZNbEqOFLoZWaJdH69FgevhQH__1SQPm9gEwa0OnNdOyEajrCFg6ei9crZyckYW2StmEi9wq_aZx7_PTjTwKeH8iO1C__DTQHSwBeJRPSNvRqc-DhJS30JCawvPnbh78hbTM137bZDrVrpCHb3D_x7xO7LLEeUPXPEjsr25fwjH0Apt3MkQ678BR5IG4g priority: 102 providerName: Elsevier |
Title | Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience |
URI | https://dx.doi.org/10.1016/j.tranon.2019.12.001 https://www.ncbi.nlm.nih.gov/pubmed/31875575 https://search.proquest.com/docview/2330792499 https://pubmed.ncbi.nlm.nih.gov/PMC6931211 https://doaj.org/article/fde42a9e228b45d99262837fcc6ba3b5 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwELaAA-qlKvS1LSBX6jWs49fGPZVFIEBahNSttDfLduw2CBJEl0t_fcdODCw9IHHJIS_bM2PPjP35M0JfVYQ-1c4VNZGm4IGYwgjqC-sFqT2tqtLFDc6zc3nyk58txGINibwXJoH2nW3226vr_bb5nbCVN9dunHFi44vZoVQsMpON19H6hLGcovfDb0wIaN4jl4BcSxj0u0h1Wqo080fi6TBgyhMhIrrwkTtKrP0rXun_qPMpePKRNzp-g14PYSQ-6Ku7hdZ8u402Z8NC-Vv0_cL8hXS4bSxuWgxBHp5nRDnuAp52rcc_wMYjOugbHshBr_AD8fE7ND8-mh-eFMNhCYUTVC2L2lEDTfTE84qo4ESQXBEIv4ISVIITl4QaVorAiIUsyQjnrK059G_ijJXsPdoAKfmPCJfUSukq51nleW1lFUMmK0IZuBUwAoxQkUWmb3pKDJ2xYpe6l7aO0tYljZC5EZpGud6_Gwmt043u9pce1KpD7Tk1ylNaWS5qFWkMIXcOzklrmBUjNMla0UNs0Pt8-FXzTPFfshI1dJ24HmJa39390ZTBABfzTzVCH3ql3lcy2weUu6LulVasPgFrTfTcg3V-evGXn9ErGrP6hA3fQRvL2zu_C6HP0u6lKQO4ni6me8ns_wF_DgYg |
link.rule.ids | 230,315,733,786,790,870,891,2115,3525,27955,27956,45907,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgEX3o_laSSu2XUc2405QSuqBbpVJRbUm2U7NgTapCrZS3894yQu3XJAcI3zsmc8_sb-_BnglYrUp8q5rKLSZDxQkxnBfGa9oJVnZZm7uMF5sS_nn_mHQ3G4ASLthelJ-87W0-boeNrU33pu5cmxmyWe2OxgsSNVEZXJZlfgKvZXJlKSPgTgmBKwtEuup3J1GPbbKHaaq37uj8bzYdCZt4SI_MILA1Kv2782Lv2JOy_TJy-MR7u34EuqyUBD-TFddXbqzi6JPP5zVW_DzRGhkrdD8R3Y8M1duLYY1-DvwZsDc4aZdlNbUjcE8SNZJrI6aQPZbhtPPmH3icSj12TUHT0ivzWV78Ny991yZ56N5zBkTjDVZZVjBtvOU89LqoITQXJFEdkFJZhEfCApM0UuQkEtJmBGOGdtxTF0UGesLB7AJja_fwQkZ1ZKVzpflJ5XVpYRjVkR8sCtwOAygSzZQp8Mahs60dC-68GMOppR5yyy8SawHQ12fm_Uyu4vtKdf9diMOlSeM6M8Y6XlolJRIRHT8uCctKawYgJbydx6hB0DnMBX1X_5_MvkHRp7ZVxqMY1vVz81KzB2xtRWTeDh4C3nP5kcD7-75kdrtVgvQe_olb9Hb3j830--gOvz5WJP773f__gEbrA4edBT0J_CZne68s8QYXX2ed-ffgFzSyYU |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFLagSBUXdsqwGolrZhzH9sScoIVRWaYaiUGquFheIdAmo5K59NfznMRlphyQes3m2O_5-Xv2588IvZKR-uSszRwROmOB6Exz6jPjOXGelmVu4wbn-ZE4_Mo-HvPjjaO-OtK-NdW4Pjkd19WPjlu5OrWTxBObLOYHQhZRmWyycmFyHd2APkunKVHvg3BMC2jaKdfRuVoI_U0UPM1lN_9H4hkx4NBTziPHcGNQ6rT7t8amf7HnZQrlxpg0u42-pdr0VJRf43Vrxvb8ktDjlap7B90akCp-2z9yF13z9T20Ox_W4u-jNwt9Dhl3XRlc1RhwJF4m0jpuAt5vao-_QDeKBKTXeNAfPcF_tZUfoOXs_fLgMBvOY8gsp7LNnKUa2s8Tz0oig-VBMEkA4QXJqQCcIAjVRc5DQQwkYppba4xjEEKI1UYUD9EOmMA_QjinRghbWl-UnjkjyojKDA95YIZDkBmhLNlDrXrVDZXoaD9Vb0oVTalyGll5I7QfjXbxbNTM7i40Z9_V0JQqOM-olp7S0jDuZFRKhPQ8WCuMLgwfoWkyuRrgRw8r4FPVf4p_mTxEQe-MSy669s36t6IFxNCY4soR2us95uInk_NBuVu-tFWL7TvgIZ0C-OARj6_85gu0u3g3U58_HH16gm7SOIfQMdGfop32bO2fAdBqzfOuS_0BpWkolA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pazopanib+in+the+Treatment+of+Bone+Sarcomas%3A+Clinical+Experience&rft.jtitle=Translational+oncology&rft.au=Aggerholm-Pedersen%2C+Ninna&rft.au=Rossen%2C+Phillip&rft.au=Rose%2C+Hanne&rft.au=Safwat%2C+Akmal&rft.date=2020-02-01&rft.issn=1936-5233&rft.volume=13&rft.issue=2&rft.spage=295&rft_id=info:doi/10.1016%2Fj.tranon.2019.12.001&rft_id=info%3Apmid%2F31875575&rft.externalDocID=31875575 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1936-5233&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1936-5233&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1936-5233&client=summon |